Synthetic phosphodiesterase type 5 (PDE5) inhibitor; N-desmethyl analogue of tadalafil
An unapproved, demethylated structural analogue of tadalafil with retained nanomolar PDE5 inhibitory potency, identified principally as a synthetic adulterant in dietary supplements marketed for sexual enhancement and as a reference standard for forensic and analytical chemistry.
Abstract
Nortadalafil (demethyl tadalafil, CAS 171596-36-4) is a synthetic analogue of the clinically approved phosphodiesterase type 5 (PDE5) inhibitor tadalafil, distinguished from the parent compound by the absence of the N-methyl substituent on the piperazinedione ring of the hexahydropyrazinopyridoindole scaffold. The compound retains nanomolar inhibitory potency against PDE5 (IC50 approximately 11 to 12 nM against bovine PDE5, compared to approximately 5 nM for tadalafil) and produces cGMP-mediated smooth muscle relaxation with EC50 values of 300 to 600 nM in rat aortic preparations. Despite this pharmacological activity, nortadalafil has never been submitted for regulatory approval in any jurisdiction and has not been the subject of controlled clinical trials in human subjects. The compound first entered the scientific literature through its detection as an undeclared adulterant in herbal and dietary supplements marketed for erectile dysfunction, a context in which it represents one member of a large and expanding family of synthetic PDE5 inhibitor analogues (including aminotadalafil, N-octylnortadalafil, chloropretadalafil, and others) introduced into the unregulated supplement market to evade analytical screening for the approved parent compounds. Analytical characterization of nortadalafil in adulterated products relies on high-performance liquid chromatography with diode-array and mass spectrometric detection, high-resolution mass spectrometry, and nuclear magnetic resonance spectroscopy. No systematic toxicology, no formal pharmacokinetic characterization in healthy volunteers under regulatory oversight, and no controlled efficacy data exist for the compound. Safety concerns are inferred from the PDE5 inhibitor class and include the absolute contraindication of concurrent nitrate administration (risk of severe, potentially fatal hypotension), the interaction with alpha-adrenergic receptor antagonists and potent CYP3A4 inhibitors, and the unknown dose-response and adverse-event profile of a compound consumed without medical supervision at uncharacterized doses in adulterated supplements. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.